Avzivi® (BAT1706) is Bio-Thera Solution’second FDA approved product in the United States Avzivi® is the second biosimilar researched,developed, and manufactured by a Chinese pharmaceutical company to receive FDAapproval in the United States Guangzhou, China – December 7, 2023 – Bio-TheraSolu...
DetailsGUANGZHOU, China--( BUSINESS WIRE )--Bio-Thera Solutions (SHA: 688177), a commercial-stage biopharmaceuticalcompany, today announced that the China National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for BAT1706, a proposed biosimilar to Avastin® (be...
GUANGZHOU, China--( BUSINESS WIRE )--Bio-Thera Solutions, a commercial-stage biopharmaceutical company, today announced that the Phase III clinical trial comparing the safety and efficacy of BAT1706 versus Avastin® 1 (bevacizumab) met its primary endpoint. BAT1706 is being developed by Bio-Thera So...
GUANGZHOU, China--( BUSINESS WIRE )--Bio-Thera Solutions, Ltd., a fully-integrated pharmaceutical company, today announced that QLETLI ® (格乐立 ® ), a biosimilar to Humira ® (adalimumab), is now available in China. QLETLI ® (格乐立 ® ), the first adalimumab biosimilar approved by the Chi...
